Understanding resistance to combination chemotherapy

Justin R. Pritchard, Douglas A. Lauffenburger, Michael T. Hemann

Research output: Contribution to journalReview article

31 Citations (Scopus)

Abstract

The current clinical application of combination chemotherapy is guided by a historically successful set of practices that were developed by basic and clinical researchers 50-60 years ago. Thus, in order to understand how emerging approaches to drug development might aid the creation of new therapeutic combinations, it is critical to understand the defining principles underlying classic combination therapy and the original experimental rationales behind them. One such principle is that the use of combination therapies with independent mechanisms of action can minimize the evolution of drug resistance. Another is that in order to kill sufficient cancer cells to cure a patient, multiple drugs must be delivered at their maximum tolerated dose - a condition that allows for enhanced cancer cell killing with manageable toxicity. In light of these models, we aim to explore recent genomic evidence underlying the mechanisms of resistance to the combination regimens constructed on these principles. Interestingly, we find that emerging genomic evidence contradicts some of the rationales of early practitioners in developing commonly used drug regimens. However, we also find that the addition of recent targeted therapies has yet to change the current principles underlying the construction of anti-cancer combinatorial regimens, nor have they made substantial inroads into the treatment of most cancers. We suggest that emerging systems/network biology approaches have an immense opportunity to impact the rational development of successful drug regimens. Specifically, by examining drug combinations in multivariate ways, next generation combination therapies can be constructed with a clear understanding of how mechanisms of resistance to multi-drug regimens differ from single agent resistance.

Original languageEnglish (US)
Pages (from-to)249-257
Number of pages9
JournalDrug Resistance Updates
Volume15
Issue number5-6
DOIs
StatePublished - Oct 1 2012

Fingerprint

Combination Drug Therapy
Pharmaceutical Preparations
Neoplasms
Therapeutics
Investigational Therapies
Systems Biology
Maximum Tolerated Dose
Multiple Drug Resistance
Drug Combinations
Drug Resistance
Research Personnel

All Science Journal Classification (ASJC) codes

  • Oncology
  • Pharmacology
  • Cancer Research
  • Infectious Diseases
  • Pharmacology (medical)

Cite this

Pritchard, Justin R. ; Lauffenburger, Douglas A. ; Hemann, Michael T. / Understanding resistance to combination chemotherapy. In: Drug Resistance Updates. 2012 ; Vol. 15, No. 5-6. pp. 249-257.
@article{3b3cf484f9784c49900f205d5e8c3d7e,
title = "Understanding resistance to combination chemotherapy",
abstract = "The current clinical application of combination chemotherapy is guided by a historically successful set of practices that were developed by basic and clinical researchers 50-60 years ago. Thus, in order to understand how emerging approaches to drug development might aid the creation of new therapeutic combinations, it is critical to understand the defining principles underlying classic combination therapy and the original experimental rationales behind them. One such principle is that the use of combination therapies with independent mechanisms of action can minimize the evolution of drug resistance. Another is that in order to kill sufficient cancer cells to cure a patient, multiple drugs must be delivered at their maximum tolerated dose - a condition that allows for enhanced cancer cell killing with manageable toxicity. In light of these models, we aim to explore recent genomic evidence underlying the mechanisms of resistance to the combination regimens constructed on these principles. Interestingly, we find that emerging genomic evidence contradicts some of the rationales of early practitioners in developing commonly used drug regimens. However, we also find that the addition of recent targeted therapies has yet to change the current principles underlying the construction of anti-cancer combinatorial regimens, nor have they made substantial inroads into the treatment of most cancers. We suggest that emerging systems/network biology approaches have an immense opportunity to impact the rational development of successful drug regimens. Specifically, by examining drug combinations in multivariate ways, next generation combination therapies can be constructed with a clear understanding of how mechanisms of resistance to multi-drug regimens differ from single agent resistance.",
author = "Pritchard, {Justin R.} and Lauffenburger, {Douglas A.} and Hemann, {Michael T.}",
year = "2012",
month = "10",
day = "1",
doi = "10.1016/j.drup.2012.10.003",
language = "English (US)",
volume = "15",
pages = "249--257",
journal = "Drug Resistance Updates",
issn = "1368-7646",
publisher = "Churchill Livingstone",
number = "5-6",

}

Understanding resistance to combination chemotherapy. / Pritchard, Justin R.; Lauffenburger, Douglas A.; Hemann, Michael T.

In: Drug Resistance Updates, Vol. 15, No. 5-6, 01.10.2012, p. 249-257.

Research output: Contribution to journalReview article

TY - JOUR

T1 - Understanding resistance to combination chemotherapy

AU - Pritchard, Justin R.

AU - Lauffenburger, Douglas A.

AU - Hemann, Michael T.

PY - 2012/10/1

Y1 - 2012/10/1

N2 - The current clinical application of combination chemotherapy is guided by a historically successful set of practices that were developed by basic and clinical researchers 50-60 years ago. Thus, in order to understand how emerging approaches to drug development might aid the creation of new therapeutic combinations, it is critical to understand the defining principles underlying classic combination therapy and the original experimental rationales behind them. One such principle is that the use of combination therapies with independent mechanisms of action can minimize the evolution of drug resistance. Another is that in order to kill sufficient cancer cells to cure a patient, multiple drugs must be delivered at their maximum tolerated dose - a condition that allows for enhanced cancer cell killing with manageable toxicity. In light of these models, we aim to explore recent genomic evidence underlying the mechanisms of resistance to the combination regimens constructed on these principles. Interestingly, we find that emerging genomic evidence contradicts some of the rationales of early practitioners in developing commonly used drug regimens. However, we also find that the addition of recent targeted therapies has yet to change the current principles underlying the construction of anti-cancer combinatorial regimens, nor have they made substantial inroads into the treatment of most cancers. We suggest that emerging systems/network biology approaches have an immense opportunity to impact the rational development of successful drug regimens. Specifically, by examining drug combinations in multivariate ways, next generation combination therapies can be constructed with a clear understanding of how mechanisms of resistance to multi-drug regimens differ from single agent resistance.

AB - The current clinical application of combination chemotherapy is guided by a historically successful set of practices that were developed by basic and clinical researchers 50-60 years ago. Thus, in order to understand how emerging approaches to drug development might aid the creation of new therapeutic combinations, it is critical to understand the defining principles underlying classic combination therapy and the original experimental rationales behind them. One such principle is that the use of combination therapies with independent mechanisms of action can minimize the evolution of drug resistance. Another is that in order to kill sufficient cancer cells to cure a patient, multiple drugs must be delivered at their maximum tolerated dose - a condition that allows for enhanced cancer cell killing with manageable toxicity. In light of these models, we aim to explore recent genomic evidence underlying the mechanisms of resistance to the combination regimens constructed on these principles. Interestingly, we find that emerging genomic evidence contradicts some of the rationales of early practitioners in developing commonly used drug regimens. However, we also find that the addition of recent targeted therapies has yet to change the current principles underlying the construction of anti-cancer combinatorial regimens, nor have they made substantial inroads into the treatment of most cancers. We suggest that emerging systems/network biology approaches have an immense opportunity to impact the rational development of successful drug regimens. Specifically, by examining drug combinations in multivariate ways, next generation combination therapies can be constructed with a clear understanding of how mechanisms of resistance to multi-drug regimens differ from single agent resistance.

UR - http://www.scopus.com/inward/record.url?scp=84870500959&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84870500959&partnerID=8YFLogxK

U2 - 10.1016/j.drup.2012.10.003

DO - 10.1016/j.drup.2012.10.003

M3 - Review article

C2 - 23164555

AN - SCOPUS:84870500959

VL - 15

SP - 249

EP - 257

JO - Drug Resistance Updates

JF - Drug Resistance Updates

SN - 1368-7646

IS - 5-6

ER -